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he Pit1-Oct1-Unc86 domain (POU domain) tran-
scription factor Brn3a controls sensory neuron sur-
vival by regulating the expression of Trk receptors
and members of the Bcl-2 family. Loss of Brn3a leads to a
dramatic increase in apoptosis and severe loss of neu-
rons in sensory ganglia. Although recent evidence sug-
gests that Brn3a-mediated transcription can be modiﬁed
by additional cofactors, the exact mechanisms are not
known. Here, we report that homeodomain interacting
protein kinase 2 (HIPK2) is a pro-apoptotic transcrip-
tional cofactor that suppresses Brn3a-mediated gene ex-
T
 
pression. HIPK2 interacts with Brn3a, promotes Brn3a
binding to DNA, but suppresses Brn3a-dependent tran-
scription of 
 
brn3a
 
, 
 
trkA
 
, and 
 
bcl-x
 
L
 
. Overexpression of
HIPK2 induces apoptosis in cultured sensory neurons.
Conversely, targeted deletion of HIPK2 leads to increased
expression of Brn3a, TrkA, and Bcl-x
 
L
 
, reduced apoptosis
and increases in neuron numbers in the trigeminal gan-
glion. Together, these data indicate that HIPK2, through
regulation of Brn3a-dependent gene expression, is a crit-
ical component in the transcriptional machinery that con-
trols sensory neuron survival.
 
Introduction
 
Programmed cell death (apoptosis) is controlled by highly
conserved mechanisms and plays important roles in the ner-
vous system during development and in pathological condi-
tions (Yuan and Yankner, 2000; Yuan et al., 2003). Among
many effectors that contribute to apoptosis, signaling mecha-
nisms transmitted through neurotrophin receptors regulate the
decision between survival and cell death during the develop-
ment of sensory neurons (Kaplan and Miller, 2000; Chao,
2003; Huang and Reichardt, 2003). Failure to acquire an ade-
quate amount of neurotrophins leads to elimination of neurons
through apoptosis. Interestingly, the expression of neurotro-
phin receptors follows a dynamic pattern during sensory neu-
rogenesis. For instance, p75NTR is expressed in the migrating
neural crest cells, but its expression is rapidly down-regulated
in differentiated sensory neurons. In contrast, expression of
TrkA, TrkB, and TrkC sharply increases in dorsal root and
trigeminal ganglia when active neurogenesis occurs (Farinas et
al., 1998; Huang et al., 1999a; Rifkin et al., 2000). Loss of
neurotrophins or Trk receptors leads to a dramatic increase in
apoptosis in selective population of sensory neurons (Farinas
et al., 1998; Huang et al., 1999a).
In contrast to the well-characterized role of Trk recep-
tors during sensory neuron development, much less is known
about the transcriptional mechanisms that control the expres-
sion of Trk receptors. Emerging evidence indicates that the
cis-regulatory element in the 
 
trkA
 
 gene is enriched with highly
conserved DNA binding sequences that can potentially recruit
transcription factors to regulate the spatial and temporal ex-
pression of TrkA (Ma et al., 2000). Indeed, analyses of mice
with a targeted deletion in Pit1-Oct1-Unc86 domain (POU do-
main) transcription factor Brn3a shows that Brn3a is essential
for survival of sensory neurons (McEvilly et al., 1996; Huang
et al., 1999b). Loss of Brn3a results in a progressive down-
regulation of TrkA expression, leading to a dramatic increase
in apoptotic cell death (Huang et al., 1999b). Consistent with
this, Brn3a binding sites have been identified in the 
 
trkA
 
 en-
hancer that are required to drive transgene expression in sen-
sory ganglia (Ma et al., 2003). Together, these data provide
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convincing evidence for a direct involvement of Brn3a in the
regulation of TrkA expression.
In addition to regulating Trk expression, Brn3a has also
been reported to regulate the expression of Bcl-2, Bcl-x
 
L
 
, and
Bax in vitro, providing another possible mechanism through
which Brn3a mediates neuronal survival (Smith et al., 1998,
2001; Budhram-Mahadeo et al., 1999; Sugars et al., 2001). Tar-
geted disruption of 
 
bax
 
 eliminates programmed cell death in
the developing nervous system, resulting in an increased num-
ber of neurons in selected populations (Deckwerth et al., 1996;
White et al., 1998). In contrast, deletion of 
 
bcl-x
 
L
 
 leads to glo-
bal and excessive apoptotic cell death in the central and periph-
eral nervous systems (Motoyama et al., 1995). Despite the crit-
ical roles of Bcl-x
 
L
 
 and Bax in neuronal survival, however, the
mechanisms by which Brn3a regulates their expression under
physiological conditions have not been fully characterized.
Brn3a responsive elements have been identified in the pro-
moter sequences of 
 
bcl-2
 
, 
 
bcl-x
 
L
 
, and 
 
bax
 
 (Smith et al., 1998,
2001), yet it is unclear if expression of these Bcl-2 members is
altered in the sensory ganglia of 
 
Brn3a
 
 
 
/
 
 
 
 mutants.
Several lines of evidence indicate that additional co-
factors may regulate Brn3a-dependent transcription. First, al-
though Brn3a expression is detected in sensory ganglia as early
as E9.5, cell death and down-regulation of Brn3a target genes
are detected only after E13.5, suggesting that Brn3a may not be
fully functional in early sensory ganglia (Fedtsova and Turner,
1995; McEvilly et al., 1996; Huang et al., 1999b). Second,
 
brn3a
 
 enhancer element-regulated 
 
 
 
-galactosidase (LacZ) ex-
pression is higher in the sensory ganglia of 
 
Brn3a
 
 
 
/
 
 
 
 mutants
than in wild-type mice, suggesting that Brn3a may negatively
regulate its own expression directly or via recruitment of tran-
scriptional corepressors (Trieu et al., 2003).
Here, we provide evidence that interaction of Brn3a and
homeodomain interacting protein kinase 2 (HIPK2) regulates
the transcription of a common set of prosurvival genes, includ-
ing TrkA and Bcl-x
 
L
 
. Whereas HIPK2 interacts with the POU
homeodomain of Brn3a and promotes Brn3a binding to DNA,
HIPK2 suppresses Brn3a auto-regulation and Brn3a target
genes. As a consequence, overexpression of HIPK2 leads to
neuronal apoptosis in cultured sensory neurons. Conversely,
 
HIPK2
 
 null mutants show up-regulation of Brn3a and Brn3a tar-
get genes in the trigeminal ganglion, which leads to reduced
apoptosis and increased neuron number in this sensory ganglion.
 
Results
 
Identification of HIPK2 as an interacting 
partner for Brn3a
 
The important roles of Brn3a in regulating its own expression
and the expression of Trk receptors and members of the Bcl-2
family motivated us to investigate additional components that
regulate Brn3a-mediated gene expression. Using the yeast two-
hybrid screen and a cDNA library prepared from mouse E10-
11 embryos (Hollenberg et al., 1995), we isolated several inde-
pendent clones that interacted with full-length Brn3a, one of
which encoded protein sequence between amino acids 752 and
897 of HIPK2, a Ser/Thr kinase that interacts with homeo-
domain transcription factors of the Nkx family (Fig. 1; Kim et
al., 1998). Further characterizations showed that full-length
Figure 1. HIPK2 interacts with Brn3a and promotes Brn3a binding to
DNA elements. (A) Isolation of HIPK2 by yeast two-hybrid screen. The do-
main between amino acids 752 and 897 of HIPK2 interacts with full-
length Brn3a, Brn3b, and Brn3c. Interaction between Brn3a and HIPK2 is
mediated by the POU homeodomain (Brn3a POUHD), not the POU specific
domain (POUS) or non-POU domain (Brn3a NP). Data represent mean  
SEM (n   3). A schematic diagram of Brn3a and HIPK2 interaction. (B)
Brn3a and HIPK2 are present in a protein complex that can be coimmuno-
precipitated with Brn3a antibody, but not preimmune sera (PI). Interaction
between Brn3a and HIPK2 is reduced by increasing wash stringency.
Whereas detergents NP-40 (1%; wash 1) and sodium deoxycholate
(0.5%; wash 2) preserve Brn3a–HIPK2 interaction, the presence of ionic
detergent SDS (0.1%; wash 3) significantly reduces such interaction. (C)
Electrophoretic mobility shift assays for Brn3a and HIPK2. HIPK2 en-
hances Brn3a binding to consensus DNA element (b3s1). Routinely, 2  l
of in vitro translated Brn3a protein is added (lanes 4–7) and increasing
amount of HIPK2 (1, 2, and 5  l) is added to the reaction (lanes 5–7). Al-
though Brn3a antibody produces a supershift, the addition of HIPK2 anti-
body does not (lanes 10–14). 
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HIPK2 also interacted with Brn3a (not depicted) and that
HIPK2 interacted with the POU homeodomain (POU
 
HD
 
) of
Brn3a, but not POU specific (POU
 
S
 
) or non-POU domain (Fig.
1, A and B). Not surprisingly, given the high sequence homol-
ogy in the POU domain among members of the Brn3 family
(
 
 
 
95%; Ryan and Rosenfeld, 1997), HIPK2 also interacted
with Brn3b and Brn3c (Fig. 1 A).
To further investigate the interaction between Brn3a and
HIPK2 in vivo, we performed coimmunoprecipitation in COS
cells that expressed Brn3a and EGFP-tagged HIPK2 (EGFP-
HIPK2). Cell lysates from COS cells were immunoprecipitated
with Brn3a antibody and probed with anti-GFP antibody in
Western blots. Our data showed that HIPK2 was present in pro-
tein complexes immunoprecipitated by Brn3a antibody, but not
by preimmune serum (Fig. 1 B, lanes 2 and 3). Interestingly,
the stability of Brn3a and HIPK2 protein complex appeared to
be influenced by increasing wash stringency, as the addition of
0.1% SDS significantly reduced protein complex formation be-
tween Brn3a and HIPK2 (Fig. 1 B, lanes 4–6).
The effect of wash stringency on the protein complex for-
mation between Brn3a and HIPK2 suggested that the interac-
tion of these two proteins might be transient or require addi-
tional components, similar to the interaction between HIPK2
and homeodomain transcription factors in the Nkx family (Kim
et al., 1998; Choi et al., 1999). To further characterize this inter-
action, we determined the effects of HIPK2 on Brn3a binding to
the consensus DNA sequence b3s1 (Trieu et al., 1999). Using in
vitro translation products of full-length Brn3a and HIPK2 pro-
teins, we showed that Brn3a formed a stable protein complex
with this sequence (Fig. 1 C, lane 4). HIPK2 enhanced Brn3a
binding, but caused no further shifting in the Brn3a–DNA com-
plex (Fig. 1 C, lanes 5–7). Furthermore, whereas addition of a
Brn3a antibody produced a supershift of the complex (Fig. 1 C,
lanes 12 and 13), addition of a polyclonal antibody that recog-
nized the COOH terminus of HIPK2 did not (Fig. 1 C, lane 14).
These results were consistent with those from coimmunoprecip-
itation and again suggested that the interaction between Brn3a
and HIPK2 may be transient or may require additional factors
(Fig. 1 B). However, we cannot completely rule out the possi-
bility that the HIPK2 antibody may not be fully capable of rec-
ognizing Brn3a–HIPK2 complex due to steric hindrance.
 
HIPK2 suppresses Brn3a auto-
regulatory activity and expression of 
Brn3a downstream targets
 
The pro-survival effect of Brn3a depends on its auto-regulatory
activity and the ability of Brn3a to up-regulate several prosur-
vival genes, including Trk receptors and members of the Bcl-2
family (Huang et al., 1999b; Smith et al., 2001; Ma et al., 2003;
Trieu et al., 2003). Indeed, the mRNA levels of TrkA and Bcl-
x
 
L
 
, as determined by quantitative RT-PCR (qRT-PCR) assays,
showed progressive down-regulation in the trigeminal ganglia
of 
 
Brn3a
 
 
 
/
 
 
 
 mutants at E13.5 and E14.5, preceding the drastic
increase in cell death at E15.5 to E17.5 (Fig. 2 A; Huang et al.,
1999b). In contrast, expression of Bcl-2 and Bax in the trigem-
inal ganglion of 
 
Brn3a
 
 
 
/
 
 
 
 mutants at the same stages remained
unchanged (Fig. 2 A). Consistent with the qRT-PCR results,
protein levels of TrkA and Bcl-x
 
L
 
 showed significant reduc-
tions in the trigeminal ganglion of 
 
Brn3a
 
 
 
/
 
 
 
 mutants at E15.5,
whereas Bax remained unchanged (Fig. 2 B). To determine if
the effect of HIPK2 on Brn3a-mediated gene expression was
direct, we used luciferase constructs that contained three syn-
thetic tandem repeats of Brn3a binding sites identified in the
 
brn3a
 
 enhancer element (Prox3), which has been shown to be a
reliable reporter for Brn3a activity. Consistent with previous
data (Trieu et al., 1999), Brn3a activated the Prox3 reporter in a
dose-dependent fashion, whereas HIPK2 by itself did not affect
the baseline level of Prox3 luciferase activity (Fig. 2 C). Inter-
estingly, addition of HIPK2 suppressed Brn3a-mediated activa-
tion of Prox3 (Fig. 2 C). To determine if expression of HIPK2
in sensory neurons leads to down-regulation of Brn3a in a more
physiological setting, we used herpes virus vectors to introduce
EGFP-HIPK2 into cultured sensory neurons (Coopersmith and
Neve, 1999), achieving almost 100% infection efficiency at
50–100 multiplicity of infection (MOI). Subsequent to infec-
tion, total RNA was extracted and mRNA converted to cDNA.
qRT-PCR assays were used to measure Brn3a mRNA levels,
which were standardized to the endogenous GAPDH level. Our
results indicated that, expression of EGFP-HIPK2 leads to a
progressive down-regulation of Brn3a mRNA in sensory neu-
rons. By 36 h after infection, Brn3a mRNA was reduced to
 
 
 
40% of that in control neurons infected with LacZ or EGFP
virus (P 
 
 
 
 0.01; Fig. 2 D).
The suppressive effect of HIPK2 on Brn3a suggests that
HIPK2 may inhibit Brn3a auto-regulation, which may in turn
lead to down-regulation of Brn3a target genes. However, it is
equally possible that HIPK2 may directly suppress the ability
of Brn3a to activate its targets. To test latter hypothesis, lu-
ciferase constructs containing 
 
trkA
 
 (two tandem repeats of 5
 
 
 
Brn3a binding site) or 
 
bcl-x
 
L
 
 (a single Brn3a binding site) en-
hancer sequences were used (Smith et al., 2001; Ma et al.,
2003). Similar to the Prox3 reporter, Brn3a significantly up-
regulated TrkA luciferase activity, whereas HIPK2 suppressed
the ability of Brn3a to activate TrkA luciferase activity (Fig. 2
E). Brn3a also activated Bcl-x
 
L
 
 luciferase activity and the addi-
tion of HIPK2 suppressed Brn3a-mediated activation of Bcl-x
 
L
 
luciferase (Fig. 2 G). Consistent with the luciferase data, addi-
tion of Brn3a to cultured sensory neurons up-regulated the ex-
pression of TrkA and Bcl-x
 
L
 
 mRNA by 
 
 
 
12- and 3-fold, re-
spectively (P 
 
 
 
 0.01, 
 
n
 
 
 
 
 
 3; Fig. 2, F and G). In contrast,
expression of HIPK2 in sensory neurons reduced TrkA mRNA
to 
 
 
 
7% and Bcl-x
 
L
 
 mRNA level to 
 
 
 
20% of control EGFP-
expressing neurons (Fig. 2, F and H). Together, these data sup-
port the notion that HIPK2 is a transcriptional corepressor that
can suppress the expression of Brn3a and Brn3a downstream
targets TrkA and Bcl-x
 
L
 
 in sensory neurons.
 
HIPK2 induces apoptosis in sensory 
neurons
 
In previous work, we showed that loss of Brn3a led to a dra-
matic loss of trigeminal neurons due to increased apoptosis
(Huang et al., 1999b). These results lead to the prediction that
suppression of Brn3a by HIPK2 should mimic Brn3a loss-of-
function phenotype and result in neuronal apoptosis. To test this 
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hypothesis, a gain-of-function approach was used to determine
the effect of HIPK2 on the survival of cultured sensory neurons.
Although herpes simplex virus (HSV)–mediated expression of
EGFP did not affect the survival of sensory neurons (Fig. 3,
A–D), expression of EGFP-HIPK2 induced apoptosis, indicated
by positive TUNEL staining, in a dose-dependent manner (Fig.
3, E–I). Ectopically expressed EGFP-HIPK2 could be detected
either diffusely in the nucleus of trigeminal neurons or in struc-
tures resembling nuclear bodies (Fig. 3 E, inset). Neurons ex-
pressing EGFP-HIPK2 showed TUNEL-positive staining as
early as 24 h after infection (Fig. 3, E–H, and J), by 96 h 
 
 
 
80%
of these neurons were dead as assessed by morphological crite-
ria (Fig. 3 J). In contrast, expression of EGFP had no effect on
survival of infected neurons (Fig. 3, I–J). To determine if the
Figure 2. HIPK2 suppresses Brn3a auto-regulatory ac-
tivity and Brn3a downstream target genes. (A) Progres-
sive down-regulation of TrkA and Bcl-xL, but not Bcl-2 or
Bax, in trigeminal ganglion of Brn3a
 /  mutants. The
mRNA levels of TrkA, Bcl-2, Bcl-xL and Bax are deter-
mined in the trigeminal ganglion of wild-type and
Brn3a
 /  embryos from E12.5 to14.5 using qRT-PCR as-
says. Although the expression levels of these genes in
Brn3a
 /  are comparable to those in wild type at E12.5,
mRNA levels of TrkA and Bcl-xL show significant down-
regulation at E13.5. By E14.5,  20% of TrkA and Bcl-xL
mRNAs are detected in the trigeminal ganglion of
Brn3a
 / . In contrast, mRNA levels of Bcl-2 and Bax in
Brn3a
 /  are comparable to those in wild type at the
same stages. Data represent mean   SEM (n   3). (B)
Consistent with the qRT-PCR results, the amounts of TrkA
and Bcl-xL protein show significant reductions in the
trigeminal ganglion of Brn3a
 /  at E15.5. In contrast, no
reduction in Bax is detected. (C) HIPK2 inhibits Brn3a-
mediated activation of luciferase construct Prox3, which
contains synthetic DNA binding elements from brn3a en-
hancer. The luciferase activities of Prox3 are presented as
mean   SEM (n   3, * indicates P   0.01, t test). The
amounts of DNA added to each reaction are indicated
below each graph. All luciferase activities are normal-
ized to Renilla luciferase reporter activity. (D) Consistent
with its ability to suppress the luciferase activity of Prox3,
expression of EGFP-HIPK2 in cultured trigeminal neurons
using HSV leads to a progressive down-regulation of
Brn3a mRNA. In contrast, expression of LacZ or EGFP in
neurons has no effect on Brn3a mRNA level. Data repre-
sent mean   SEM (n   3, ns indicates no significant dif-
ference and * indicates P   0.01, t test). (E) HIPK2 inhib-
its Brn3a-mediated activation of the TrkA luciferase
activity. TrkA luciferase construct contains two Brn3a
binding sites identified in the 5 -end of trkA promoter (Ma
et al., 2003). TrkA luciferase activities, measured 24 h
after transfection, are expressed as fold change com-
pared with control. Values are expressed as mean  
SEM (n   3). * Indicates P   0.01 using t test. (F) HIPK2
down-regulates TrkA mRNA level to  10% of that in neu-
rons expressing EGFP. In contrast, Brn3a up-regulates the
mRNA of TrkA in cultured sensory neurons by at least 12-
fold. Changes in the level of TrkA mRNA are determined
using qRT-PCR assays and standardized to GAPDH. Neu-
rons are collected for RNA extraction 48 h after infection.
qRT-PCR assays are done in triplicates and at least three
samples from each treatment are examined. Data repre-
sent mean   SEM. (G) HIPK2 also inhibits Brn3a-medi-
ated activation of Bcl-xL luciferase activity. Data represent
mean 6 SEM (n   3, * indicates P   0.01, t test). (H) Ex-
pression of EGFP-HIPK2 down-regulates the endogenous
level of Bcl-xL mRNA in cultured sensory neurons to
 20% of that in neurons expressing EGFP. In contrast,
expression of Brn3a increases Bcl-xL mRNA by more than
threefold. Data represent mean   SEM (n   3).HIPK2 SUPPRESSES BRN3A-MEDIATED GENE EXPRESSION • WIGGINS ET AL. 261
pro-apoptotic function of HIPK2 was solely dependent on its
interaction with Brn3a, we examined the effect of HIPK2 ex-
pression in sensory neurons of Brn3a
 /  mutants. One would
predict that if HIPK2 function depends exclusively on its ability
to suppress Brn3a, HIPK2-induced apoptosis should be attenu-
ated in Brn3a
 /  neurons. Alternatively, if HIPK2 continues to
induce apoptosis in these neurons, it is likely that HIPK2 may
also activate additional Brn3a-independent cell death mecha-
nisms. Our results indicated that, similar to the data in J,  30%
of wild-type and Brn3a
 /  neurons survived at 72 h after infec-
tion with HSV-HIPK2 (Fig. 3 K). However, significantly fewer
( 10%) neurons from Brn3a
 /  mutants survived under the
same treatment (Fig. 3 K). These results support the notion that
HIPK2 and Brn3a antagonize each other and the interaction be-
tween these two regulates a delicate balance of gene expression
critical for neuronal survival. They also suggest that over-
expression of HIPK2 in the absence of Brn3a can lead to sig-
nificantly more apoptosis, probably due to activation of
Brn3a-independent cell death pathway(s) (D’Orazi et al., 2002;
Hofmann et al., 2002; Zhang et al., 2003).
Expression of HIPK2 during sensory 
neurogenesis
To begin to understand the in vivo function of HIPK2, espe-
cially in the context of sensory neuron survival during develop-
ment, we investigated the expression pattern of HIPK2. In situ
hybridization using an RNA probe derived from the 39 UTR in-
dicated that HIPK2 mRNA was present in the developing
sensory ganglia, including the trigeminal, vestibulocochlear,
nodose-petrosal, and dorsal root ganglia (Fig. 4 A). HIPK2
mRNA was also detected in mid-brain/hindbrain regions and in
nonneural tissues, such as liver, heart, and kidney (Fig. 4 A and
not depicted). Using an antibody that recognized the COOH ter-
minus of HIPK2, HIPK2 was detected in the developing
trigeminal and dorsal root ganglia at E12.5 (Fig. 4, C, F, and G).
In contrast to the more restricted expression of Brn3a, HIPK2
protein was also detected in the developing spinal cord (Fig. 4,
B and C). Interestingly, whereas Brn3a was confined to the nu-
clei, the distribution of HIPK2 appeared to be more heteroge-
neous. At E12.5, some neurons showed dense nuclear staining,
whereas the staining in others was more diffuse (Fig. 4, F and
G, arrows). The presence of HIPK2 protein in the neuronal cy-
toplasm appeared to be more distinct at postnatal stages, sug-
gesting that the subcellular localization of HIPK2 may change
at different stages of neuronal development (not depicted).
Targeted deletion of HIPK2 gene
The suppressive effects of HIPK2 in vitro and the coexpression
of Brn3a and HIPK2 in sensory ganglia suggest that both may be
important components in the transcriptional mechanism that con-
trols sensory neuron survival and cell death by regulating a com-
mon set of prosurvival genes. To test this hypothesis, we deleted
HIPK2 in embryonic stem (ES) cells. The mouse HIPK2 locus
encompasses  150 kb and contains 16 exons (unpublished data).
We targeted exon 3, which encodes the first ATG and the entire
HIPK2 kinase domain (from amino acids 192 to 520). The ma-
jority of exon 3 was replaced with the reporter gene LacZ, fol-
lowed by a polyadenylation signal sequence and the selection
marker neomycin gene. Four positive ES clones were identified
by Southern blot analysis using specific 5  and 3  probes, three
were injected into blastocysts (Fig. 5, A and B). Germline trans-
mission of the targeted allele was confirmed by Southern blot
analyses (Fig. 5 C). Northern blot analysis using a probe that hy-
bridized with a sequence in the exons 3 and 4 confirmed that
HIPK2 mRNA was undetectable in mouse embryonic fibroblasts
(MEFs) derived from homozygous HIPK2 (HIPK2
 / ) mutants
Figure 3. HIPK2 induces neuronal apoptosis. (A–H)
Although EGFP has no effect on the survival of
cultured trigeminal neurons (A–D), EGFP-HIPK2 in-
duces apoptosis (highlighted by TUNEL stain)
(E–H). The distribution of EGFP-HIPK2 varies in
neurons, with some showing diffuse localization
in the nucleus and others in structures similar to
nuclear bodies (E, inset). (I and J) HIPK2-induced
apoptosis is dose dependent. More than 50% of
neurons die at 72 after the addition of 50 MOI of
EGFP-HIPK2 HSV, whereas neurons infected by
EGFP at 350 MOI have only slight reduction in
survival (I). Neurons expressing EGFP-HIPK2 un-
dergo apoptosis over a period of 3–4 d. By the
fourth day,  70% of neurons expressing EGFP-
HIPK2 show morphological features consistent
with cell death, whereas  80% of neurons ex-
pressing EGFP continue to survive (J). Dosage of
HSV used in J is 100 MOI for both EGFP and
EGFP-HIPK2. All data represent mean   SEM
(n   3). (K) Compared with wild type or Brn3a
 / ,
overexpression of HIPK2 induces significantly
more apoptosis in Brn3a
 /  trigeminal neurons
(wild type,  n    4, Brn3a
 / ,  n    10, and
Brn3a
 / , n   8, t test, * indicates P   0.05).JCB • VOLUME 167 • NUMBER 2 • 2004 262
(Fig. 5 D). The absence of HIPK2 transcripts in the trigeminal
ganglion of HIPK2
 /  mutants was further confirmed by RT-
PCR using primers that detected sequences in exon 3 and in ex-
ons 15–16 of HIPK2 (Fig. 5 E). The insertion of LacZ in–frame
with the coding sequence of HIPK2 (HIPK2
LacZ) provided an ex-
cellent lineage tracer for cells expressing HIPK2. Consistent with
the in situ hybridization and immunostaining results (Fig. 4), sig-
nificant HIPK2
LacZ staining intensity was detected in the devel-
oping sensory ganglia, including the trigeminal and dorsal root
ganglia, diencephalon, and spinal cord at E13.5 (Fig. 5, F and G).
Loss of HIPK2 results in up-regulation of 
Brn3a and Brn3a target genes
The coexpression of Brn3a and HIPK2 in sensory ganglion and
the suppressive effects of HIPK2 on Brn3a-mediated gene ex-
pression suggest that loss of HIPK2 could lead to increases in
Figure 4. Expression of HIPK2 in the developing sensory nervous system. (A) HIPK2 mRNA is present in the sensory ganglia, including trigeminal ganglion
(TG), vestibulocochlear ganglion (VCG), nodose-petrosal ganglion (NP), and the dorsal root ganglia (DRG) at E12.5. Li, liver. (B–G) Antibodies detect
Brn3a and HIPK2 proteins in the DRG (B–D, and F) and TG (E and G) at E12.5. The staining intensity of HIPK2 appears to vary among neurons at E12.5
with a few showing more intense HIPK2 staining (F and G, arrows). Bars: (A) 500  m; (B and C) 200  m; (D–G) 50  m.
Figure 5. Targeted deletion of HIPK2 and
generation of HIPK2 null mice. (A) Homolo-
gous recombination with the targeting con-
struct deletes exon 3 (1st coding exon), and si-
multaneously inserts LacZ and a selection
marker  neomycin (PGK-neo) gene in-frame
with the first ATG of HIPK2. Arrows indicate
the orientation of PGK-neo, thymidine kinase
(hsv-tk) and LacZ genes. Primers 1–3 are used
for genotyping. (B) Genomic DNA from G418-
resistant ES colonies was screened by South-
ern blots using 5  and 3  probes indicated in
A. (C) Southern blot genotyping of wild type
(wt), HIPK2
 /  ( / ), and HIPK2
 /  ( / )
progeny using the same probes. (D) Total RNA
from MEFs derived from wild type, HIPK2
 / ,
and  HIPK2
 /  mutants was probed with a
cDNA fragment containing 5  UTR and first
coding exon of HIPK2. Level of HIPK2 expres-
sion is reduced in HIPK2
 /  mutants and is
completely absent in HIPK2
 /  mutants. (E)
mRNA from trigeminal ganglia was amplified
by RT-PCR using primers for the first coding
exon (exon 3) of HIPK2 and the last two exons
(exon 15–16). Consistent with results from the
Northern blot, HIPK2 expression is not de-
tected in the trigeminal ganglion of HIPK2
 / 
mutants. (F and G) The presence of LacZ in
HIPK2 locus provides a convenient tool to de-
tect HIPK2 expression in the developing trigem-
inal ganglion (F) and dorsal root ganglion (G)
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the expression of Brn3a and its downstream targets. To test this
hypothesis, we used qRT-PCR assays to determine the mRNA
levels of Brn3a, TrkA, Bcl-xL, and Bax in trigeminal ganglion
from individual wild-type and HIPK2
 /  embryos collected at
E13.5, 14.5, and 15.5. Loss of HIPK2 resulted in a significant
increase in Brn3a, TrkA, and Bcl-xL mRNA at E14.5 and
E15.5, with no significant change at E13.5. Specifically, the
level of Brn3a mRNA increased by 2.7-fold at E14.5 and two-
fold at E15.5 (Fig. 6 A; P   0.01, t test). The levels of TrkA and
Bcl-xL mRNA also showed significant, albeit smaller increases
at E14.5 and E15.5 (Fig. 6 A). In contrast, the level of Bax
mRNA remained unchanged from E13.5 to E15.5. Although
Brn3a mRNA showed no significant increase at E13.5, Brn3a
protein was modestly increased in some HIPK2
 /  mutants at
E13.5 ( 1.2-fold), suggesting that HIPK2 may also regulate
Brn3a protein stability at this stage (Fig. 6 B). At E15.5, the
protein levels of Brn3a, TrkA, and Bcl-xL proteins showed con-
sistent increases by 2.6-, 1.6-, and 1.7-fold, respectively (Fig. 6
B). In contrast, levels of Bcl-2 and Bax proteins were not al-
tered at any time point examined. Together, increases in the
mRNA and proteins of Brn3a, TrkA, and Bcl-xL in the trigemi-
nal ganglion of HIPK2
 /  mutants suggest that HIPK2 nega-
tively regulates Brn3a-mediated gene expression in vivo.
Reduced apoptosis and increased neuron 
number in trigeminal ganglion of HIPK2
 /  
mutants
Previous data have indicated that loss of Brn3a, TrkA, or Bcl-
xL results in prominent cell death and dramatic loss of neurons
in developing sensory ganglia (Motoyama et al., 1995; Huang
et al., 1999a,b). Hence, the observed increase in the expres-
sion of Brn3a, TrkA, and Bcl-xL in the trigeminal ganglion
of HIPK2
 /  mutants should create a condition rendering
HIPK2
 /  sensory neurons more resistant to apoptosis during
development (Ensor et al., 2001). To test this possibility, we
determined the number of neurons undergoing apoptosis and
the total number of neurons in the trigeminal ganglion of wild-
type and HIPK2
 /  mutants at different developmental stages.
In the wild-type trigeminal ganglion, apoptotic profiles were
detected as early as E10.5 and reached a maximum between
E11.5 to E13.5, followed by a progressive decline at E15.5 and
P0 (Fig. 7, A, C, and E; Huang et al., 1999b). Most of the apop-
totic profiles stained positive for neurofilament, indicating that
they are indeed neurons (Fig. 7 A, arrowheads). Whereas the
number of apoptotic neurons was similar between wild type
and HIPK2
 /  at E10.5 and E11.5, there was significantly re-
duced apoptosis in the mutant ganglion at E13.5, E15.5, and P0
(Fig. 7, B, C, and E; 50–60% reduction, P   0.01; t test). In
agreement with this, there were significantly more neurons in
the HIPK2
 /  ganglion at E13.5 and P0 (0.01   P   0.025 at
E13.5 and P   0.01 at P0, n   4, t test). Thus, these data indi-
cate that loss of HIPK2 leads to up-regulation of Brn3a and its
target genes and reduces apoptotic cell death during the devel-
opment of sensory ganglia.
Discussion
Maintenance of neuronal survival depends on a balanced ex-
pression of prosurvival and proapoptotic genes. Results from
this work demonstrate that transcriptional corepressor HIPK2
negatively regulates Brn3a-mediated neuronal survival in the
developing sensory ganglia. The mechanism by which HIPK2
regulates Brn3a is mediated through protein–protein interac-
tion, which suppresses the Brn3a-dependent transcription of
brn3a, trkA, and bcl-xL loci. As a consequence, overexpres-
sion of HIPK2 mimics the phenotype of the Brn3a
 /  mu-
tants, resulting in apoptotic cell death in cultured sensory
neurons. Conversely, loss of HIPK2 leads to a stage-specific
up-regulation of Brn3a and Brn3a target genes, reduced apop-
tosis, and increased neuron number in the trigeminal ganglion
in vivo. Together, these data support the model that interac-
tion between Brn3a and HIPK2 regulates gene expression,
apoptosis, and neuronal survival during trigeminal ganglion
development (Fig. 8 A). Due to their important roles in regu-
Figure 6. Stage-specific up-regulation of Brn3a, TrkA, and Bcl-xL in the
trigeminal ganglion of HIPK2
 /  mutants. (A) The mRNA levels of Brn3a,
TrkA, Bcl-xL, and Bax in the trigeminal ganglion of HIPK2
 /  mutants and
wild-type littermates are determined using qRT-PCR assays. No alteration
in the mRNA level is detected at E13.5. In contrast, significant increases in
the mRNA levels of Brn3a, TrkA, and Bcl-xL are present at E14.5 and
E15.5. The level of Bax mRNA level remains unchanged from E13.5 to
E15.5. The numbers of samples examined for each age group are: E13.5,
n   3; E14.5, n   3; and E15.5, n   5. All data represent mean   SEM.
ns indicates no significant difference and * indicates P   0.01 (t test). (B)
Western blot and quantitative analyses of protein expression in trigeminal
ganglion of HIPK2
 /  mutants and wild-type littermates. At E13.5, only
Brn3a protein shows a modest increase in the trigeminal ganglion of
HIPK2
 /  mutants, whereas the protein levels of TrkA, Bcl-xL, Bcl-2, and
Bax remain unchanged. In contrast, the protein levels of Brn3a, TrkA, and
Bcl-xL increase by 2.6-, 1.6-, and 1.7-fold in HIPK2
 /  mutant trigeminal
ganglion at E15.5, whereas the levels of Bax and Bcl-2 show no change.JCB • VOLUME 167 • NUMBER 2 • 2004 264
lating the expression of TrkA and Bcl-xL, loss of Brn3a or
HIPK2 leads, respectively, to either increased or reduced pro-
grammed cell death (Fig. 8 B).
It is well-established that a cascade of transcriptional fac-
tors controls the specification of cell fate and determination of
cell survival and differentiation during the development of sen-
sory ganglia (Anderson, 1999). For instance, expression of the
basic helix-loop-helix factors Ngn1 and Ngn2 promotes neu-
ronal fate in cranial and spinal sensory ganglia (Ma et al., 1998,
1999). Indeed, ectopic expression of Ngn1 results in ectopic
Brn3a and TrkA expression in mesenchymal cells (Greenwood
et al., 1999). In contrast, characterization of Brn3a
 /  mutants
indicates that Brn3a is essential for survival and differentiation
of sensory neurons, but not neuronal cell fate specification
(Huang et al., 1999b, 2001; McEvilly et al., 1996; Xiang et al.,
1996; Eng et al., 2001). In the trigeminal ganglion of Brn3a
 / 
mutants,  70% of the neurons undergo apoptotic cell death be-
tween E15.5 and E17.5 (Fig. 8 B). Mechanisms of apoptotic
cell death in Brn3a
 /  mutant sensory ganglia involve disrup-
tion of neurotrophin signaling as a result of a progressive
down-regulation of TrkA (Fig. 2; Huang et al., 1999b; Ma et
al., 2003). In addition, the current work also demonstrates that
Brn3a is required for the maintenance of Bcl-xL in vivo with a
time course similar to that of TrkA (Fig. 2).
Recent analyses of cis-regulatory elements in trkA,
brn3a, and bcl-xL extend these in vivo findings and provide
convincing data for a direct involvement of Brn3a in transcrip-
tional control of these target genes (Trieu et al., 1999; Ma et al.,
2000, 2003; Smith et al., 2001). Mutations in Brn3a-binding
sites abolish the ability of the trkA enhancer to drive transgene
expression in sensory neurons (Ma et al., 2003). Similar to the
trkA enhancer, multiple Brn3a binding sites have also been
identified in the brn3a enhancer (Trieu et al., 1999). Brn3a ac-
tivates luciferase constructs containing these binding sites, con-
sistent with the notion that Brn3a positively regulates its own
expression through a feed forward mechanism (Fig. 2 and
Fig. 8 A; Trieu et al., 1999). Interestingly, all the Brn3a bind-
ing sites are located several kilobases upstream from the tran-
scriptional initiation site, suggesting that a long-range control
through the recruitment of multiple transcriptional cofactors
may regulate Brn3a expression. Indeed, analyses of Brn3a au-
toregulation in transgenic mice expressing LacZ under the con-
trol of brn3a enhancer indicate that, rather than activating,
Brn3a suppresses its own expression at the early stages of sen-
sory ganglion development (Trieu et al., 2003). These observa-
tions have led to the hypotheses that either Brn3a suppresses its
own expression or a yet unidentified transcriptional corepres-
sor may inhibit Brn3a functions in a stage-dependent manner
Figure 7. Reduced apoptosis and increased neuron
numbers in the developing trigeminal ganglion of
HIPK2
 /  mutants. (A–D) At E11.5, the number of neu-
rons undergoing apoptosis is similar in the trigeminal
ganglion of wild-type (A) and HIPK2
 /  mutants (B; ar-
rowheads highlight apoptotic profiles that are neurofila-
ment positive). In contrast, neuronal apoptosis in the
trigeminal ganglion is significantly reduced in HIPK2
 / 
mutants at E13.5 (C and D). Bar, 20  m. (E) Quantifica-
tion of neuronal apoptosis in the trigeminal ganglion of
wild-type and HIPK2
 /  mutants from E10.5 to postnatal
day 0 (P0). Although no difference is detected at E10.5
and E11.5, trigeminal ganglion in HIPK2
 /  mutant show
much reduced apoptosis at E13.5, E15.5 and P0 (P  
0.01, t test). (F) Number of neurons, as assessed by neu-
rofilament-positive cells, is increased in HIPK2
 /  mutants
at E13.5 (0.01   P   0.025) and at P0 (P   0.01, t
test). Data represent mean   SEM (n   4).HIPK2 SUPPRESSES BRN3A-MEDIATED GENE EXPRESSION • WIGGINS ET AL. 265
(Trieu et al., 2003). Data from this current work favor the latter
hypothesis and indicate that HIPK2 is a candidate corepressor
that suppresses Brn3a auto-regulation and Brn3a target genes.
Consistent with this model, removal of HIPK2 results in up-
regulation of Brn3a, TrkA, and Bcl-xL, a reduction in apoptosis
during the period of programmed cell death, and a slight in-
crease in neuron numbers during the development of trigeminal
ganglion (Figs. 6 and 7).
A diversity of molecular mechanisms contributes to the
execution of cell death through the canonical and noncanonical
pathways (Yuan et al., 2003). The extensive cell death in the
sensory ganglia of trkA
 /  and bcl-xL
 /  mutants coincides with
the period of programmed cell death in these ganglia and under-
scores the important roles of these two molecules in the canoni-
cal cell death pathway (Motoyama et al., 1995; Huang et al.,
1999a; Yuan et al., 2003). The fact that Brn3a regulates the ex-
pression of TrkA and Bcl-xL indicates that Brn3a-mediated
transcriptional regulation is an integral regulatory component of
the cell death process. Loss of Brn3a leads to down-regulation
of TrkA and Bcl-xL, which precedes and most definitively con-
tributes to the dramatic increase in cell death observed in the
trigeminal ganglia of Brn3a
 /  mutants (Huang et al., 1999b;
Ma et al., 2003). The reduced apoptosis observed in the trigem-
inal ganglion of HIPK2
 /  mutants provides supporting evi-
dence that the interaction between Brn3a and HIPK2 regulates a
delicate balance of gene expression that is critical for cell death.
Interestingly, however, loss of HIPK2 appears to have no effect
on apoptosis in the trigeminal ganglion at E10.5 or E11.5.
Rather, the reduction in neuronal apoptosis in HIPK2
 /  mu-
tants is most significant at E13.5, E15.5, and P0, with a slight
increase in neuron number at the same stages (Fig. 7, E and F;
Fig. 8 B). One possible explanation for the lack of a detectable
effect at the early stage of programmed cell death in HIPK2
 / 
mutant is that the efficiency of HIPK2-mediated suppression of
Brn3a may require the formation of a larger and more effective
corepressor complex. Indeed, recent data have indicated that
HIPK2 can interact with additional corepressors, including
Groucho, histone deacetylase (HDAC) and CtBP (Choi et al.,
1999; Zhang et al., 2003). Thus, if a larger HIPK2-based core-
pressor complex does exist in vivo, removal of more than one
component of this complex may be required to produce a more
significant change in Brn3a-mediated gene expression.
Given the role of HIPK2 as a transcriptional repressor,
how might the activity of HIPK2 be regulated during sensory
neuron development? Recent evidence indicates that transcrip-
tional corepressors of class II HDACs show a progressive
switch from nucleus to the cytoplasm during muscle cell differ-
entiation, whereas muscle specific transcription factor MEF re-
mains constantly in the nucleus (McKinsey et al., 2000). Nu-
clear export of HDACs is regulated by Ca
2  signals at the cell
surface and by the subsequent activation of calcium-calmodulin
kinases (McKinsey et al., 2000). Due to the interaction between
HIPK2 and HDAC (Choi et al., 1999), it is tempting to speculate
that a similar mechanism may regulate HIPK2 functions during
sensory neuron development. Future more in-depth analyses of
HIPK2 protein distribution should help test this hypothesis. Al-
ternatively, it is possible that other signaling pathways, such as
those involving neurotrophins, TGF  and Wnts, may also regu-
late the subcellular localization of HIPK2 or its interaction with
other proteins (Harada et al., 2003; Kanei-Ishii et al., 2004).
In addition to its ability to interact with Brn3a, HIPK2 has
also been shown to interact with several other factors that are
important for cell survival and apoptosis, most notably, p53 and
CtBP (D’Orazi et al., 2002; Hofmann et al., 2002; Zhang et al.,
2003). Indeed, overexpression of HIPK2 in Brn3a
 /  sensory
neurons or sympathetic neurons, which do not depend on Brn3a
for survival (Ensor et al., 2001), continues to cause apoptotic
cell death (Fig. 3 K; unpublished data). These results support the
notion that HIPK2 can activate additional Brn3a-independent
cell death pathways and that such mechanisms might become
more prominent in the absence of Brn3a (Fig. 3 K). Unlike
Brn3a, TrkA, Bcl-xL, or HIPK2, however, the level of CtBP ex-
pression is extremely low in the sensory ganglia, making it a
less likely contributor to sensory neuron survival (Hildebrand
and Soriano, 2002; unpublished data). In contrast, the reported
antagonistic roles of Brn3a and p53 in transcriptional regulation
of Bcl-xL raises the interesting possibility that, in addition to
suppressing Brn3a, HIPK2, and p53 may cooperatively suppress
Bcl-xL expression (Sugars et al., 2001). Alternatively, HIPK2
could potentially up-regulate p53-dependent activation of Bax
(Budram-Mahadeo et al., 2002). Our data indicate that the level
of Bax is essentially unchanged in either Brn3a
 /  or HIPK2
 / 
mutants (Figs. 2 and 7) and we did not detect any synergistic ef-
fect of HIPK2 and p53 on Bax or Bcl-xL luciferase activity
Figure 8. Proposed model for Brn3a and
HIPK2 in transcriptional control of gene ex-
pression in sensory neurons. (A) HIPK2 is a
transcriptional corepressor for Brn3a-mediated
gene expression. HIPK2 interacts with Brn3a
and suppresses Brn3a auto-regulatory activity
and Brn3a downstream targets, including TrkA
and Bcl-xL. (B) In control (wild type) trigeminal
ganglion, programmed cell death can be de-
tected from E10.5 to E15.5, and reaches its
maximum at E11.5 and E13.5. Due to the
opposing effects of Brn3a and HIPK2 in regu-
lating the expression of TrkA and Bcl-xL, loss of
Brn3a leads to increase in neuronal apoptosis
and expansion of the period of programmed
cell death in trigeminal ganglion at E15.5
and E17.5. In contrast, loss of HIPK2 leads to
reduced apoptosis at E13.5 and E15.5.JCB • VOLUME 167 • NUMBER 2 • 2004 266
(unpublished data). Future investigations using genome-wide
screens for the expression of p53-dependent genes in HIPK2
 / 
mutants should provide more information regarding common
target genes that are regulated by both HIPK2 and p53.
Materials and methods
Yeast two-hybrid screen, coimmunoprecipitation, and Western blot analyses
To identify Brn3a cofactors, we screened a yeast two-hybrid cDNA library
prepared from E10.5-11.5 mouse embryos (Hollenberg et al., 1995). Of
the 10
7 transformants, 67 were His
  and LacZ
 . After ruling out false-pos-
itive clones, nine clones showed specific interactions with full-length
Brn3a. Among these, five interacted with the POU domain of Brn3a, but
not the non-POU domain. Sequencing data showed that this clone en-
coded partial sequence (amino acids 782–897) of HIPK2 (Kim et al.,
1998). To further define which region in Brn3a interacted with HIPK2, we
prepared yeast constructs that contained only the POU-specific domain
(POUS) or POU homeodomain (POUHD) and determined their ability to
interact with HIPK2 (amino acids 752–897) in liquid X-gal assays. Full-
length HIPK2 cDNA was provided by Y. Kim (National Institutes of Health,
Bethesda, MD).
For coimmunoprecipitation, COS cells were transfected with EGFP-
HIPK2 and Brn3a cDNA using LipofectAMINE (Invitrogen). Cell lysates
were collected 48 h after transfection in RIPA buffer. Supernatant was in-
cubated for 1–2 h at 4 C with Brn3a antibody and with protein A/G aga-
rose beads (Santa Cruz Biotechnology, Inc.) overnight at 4 C. Beads were
washed in buffers containing 1% NP-40 (wash 1), 1% NP-40/0.5% so-
dium deoxycholate (wash 2), and 1% NP-40/0.5% sodium deoxycho-
late/0.1% SDS (wash 3). EGFP-HIPK2 was detected with anti-GFP (BD Bio-
sciences). Quantification of the protein levels in Western blots (Fig. 6 B)
was performed using the NIH Image program (developed at the National
Institutes of Health and available at http://rsb.info.nih.gov/nih-image/).
A central lane that contained proteins from HIPK2
 /  trigeminal ganglia
was spliced out in Fig. 6 B according to the guidelines by JCB (Rossner
and Yamada, 2004).
Luciferase assays and EMSA
The luciferase reporter constructs for Brn3a and Bcl-xL (provided by E.
Turner, University of California, San Diego, San Diego, CA; and G. Pack-
ham, Imperial College, London, UK) have been characterized previously
(Budhram-Mahadeo et al., 1999; Trieu et al., 1999; Sugars et al., 2001;
Thornborrow et al., 2002). The TrkA luciferase construct was prepared by
placing two tandem repeats of 5 -end Brn3a binding site in trkA promoter
into pGL3-basic (Promega; Ma et al., 2003). To determine the effects of
Brn3a and HIPK2 on the activity of these promoters, 293 cells (1.5   10
5)
were transfected with Brn3a and EGFP-HIPK2 cDNA at designated con-
centrations. The total amount of DNA added was normalized using
pcDNA3.1. Measurement of luciferase activity was done using the dual lu-
ciferase system using TD 20/20 luminometer (Turner Designs). The effects
of HIPK2 in Brn3a binding to the consensus DNA sequence (b3s1) were
determined using in vitro translated full-length Brn3a and HIPK2 protein
(Coupled TNT System; Promega; Liu et al., 2000).
In situ hybridization and immunohistochemistry
Two relatives of HIPK2, HIPK1, and HIPK3, were reported to share high
DNA sequence homology with HIPK2 (Kim et al., 1998). To circumvent
the problem of cross reactivity, a 600-bp probe from the 3  UTR of HIPK2
was isolated. Sequence homology of this probe to similar regions in
HIPK1 and HIPK3 is  40%. Northern blot analyses using this probe
showed a very different expression pattern from that of HIPK and HIPK3,
and sense probes were used as negative controls and showed no detect-
able signals. A pAb recognizing NF150 was used (CHEMICON Interna-
tional, Inc.). Brn3a antibody was previously characterized (Huang et al.,
1999a, 2001) and HIPK2 antibody was generated in rabbits using a mal-
tose binding protein fused with COOH terminus of HIPK2 (MBP-HIPK2C)
and purified using GST-HIPK2C affinity column.
Sensory neuron cultures
Trigeminal ganglia from P0-P2 mice were trypsinized and triturated in 1 ml of
F-14 culturing medium with a fire-polished siliconized Pasteur pipette. The dis-
sociated cell suspension was diluted and plated in F-14 culturing medium in
tissue culture dishes or slide chambers. NGF (10 ng/ml) or glia-derived neu-
rotrophic factor (50 ng/ml, for cultures of Brn3a
 /  neurons; Huang et al.,
1999b) was added to the medium at the time of plating. For real-time PCR
experiments, cells were plated at a density of  2,500 cells per dish,
whereas for cell counting and immunohistochemical analysis,  300 cells per
dish were plated. After plating, cells were incubated at 37 C for 3 d before
infection with HSV. The preparation of recombinant HSV carrying EGFP-
HIPK2 or Brn3a was generated using the standardized methods and the titers
of HSV were determined using PC12 cells (Coopersmith and Neve, 1999).
Assessment of cell survival and apoptosis
The number of living neurons in culture was determined by counting the neu-
rons within a marked grid in the center of the culture dishes before HSV in-
fection and at various times after infection. Neurons were observed by
phase-contrast microscopy (model TE2000U; Nikon). Living neurons were
identified as having a smooth, spherical, bright cell body and multiple neu-
rites, whereas dead cells had a shrunken irregular cytoplasm and either
fragmented or complete loss of neurites. Apoptosis was assessed using
TUNEL with the in situ cell death detection kit, TMR red (Roche Molecular
Biochemicals). Cells were analyzed using a three laser confocal microscope
(model TCS SP; Leica) and were considered to be apoptotic by the presence
of condensed, TUNEL positive nuclear material accompanied by shrinking
of the cytoplasm and loss of axons. Laser intensity (measured as the PMT
levels) for each fluorophor was kept within the linear range. Images were
captured using confocal software (Leica) and imported into Photoshop 7.0.
Countings of apoptotic neurons and total neuron number in the trigeminal
ganglion were performed as described previously (Huang et al., 1999a,b).
qRT-PCR assays
A qRT-PCR technique was used to measure the levels of TrkA, Bcl-xL,
Brn3a, and Bax mRNAs. Total RNAs were extracted using an RNeasy Kit
(QIAGEN). Reverse transcription reactions were performed using random
hexamer primers and the SuperScript first-strand synthesis system (Invitro-
gen). Quantification of cDNA was done on ABI Prism 7900HT detection
system (PE Applied Biosystems). The levels of GAPDH were also quantified
allowing TrkA, Bcl-xL, Brn3a, and Bax expression to be calculated relative
to GAPDH mRNA.
Gene targeting of HIPK2 and generation of HIPK2 null mice
Murine HIPK2 genomic DNA was isolated from a mouse 129/SvJ   li-
brary (Stratagene) using a cDNA probe containing the first coding exon
(exon 3) of HIPK2. Recombination arms were generated by PCR and sub-
cloned into the targeting vector pPNT, which contained neomycin (PGK-
neo) and thymidine kinase (hsv-tk) genes (Tybulewicz et al., 1991). The
reporter gene LacZ, followed by a poly(A) sequence, was inserted in
frame with the first ATG of HIPK2. The targeting construct was electropo-
rated into 129SvJ ES cells and selected with both G418 and gancyclovir.
Genomic DNA from G418-resistant ES colonies was digested with Nhe1
and Xba1 and screened with 5  and 3  probes. 5  probe detected a 8.8-
kb Nhe1 fragment in wild-type allele and a 14-kb fragment in mutant al-
lele, whereas 3  probe detected a 7.6-kb Xba1 fragment in wild-type
allele and a 12.8-kb fragment in mutant allele. Three independent ES
lines were injected into C57Bl/6J blastocysts. Chimeras were mated to
C57Bl/6J females to generate F1 heterozygotes. All mice were main-
tained in 129 and B6 mixed background. Animal care was performed
according to the Institute of Animal Care and Use Committee guidelines.
Genotypes were confirmed by Southern blot and PCR analysis. Northern
blots using mRNA from MEFs and a probe containing exons 3 and 4 was
performed to confirm the absence of HIPK2 expression. RT-PCR was also
performed on mRNA from MEFs and trigeminal ganglia by using primers
for the first coding exon (exon 3) of HIPK2 and the last two exons (exon
15 and 16).
Online supplemental material
The sequences of primers and probes used in qRT-PCR and genotyping of
HIPK2 mutants and the experimental details are available in Table S1
(primers and probes for qRT-PCR for Brn3a and its target genes), Table S2
(primers for HIPK2 mutant mice genotyping), and Table S3 (primers for RT-
PCR to detect HIPK2 cDNA). Online material is available at http://
www.jcb.org/cgi/content/full/jcb.200406131/DC1.
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